AMA Home Online Series Home Course Home References Print Course
CME Information
Introduction
Nonpharmacologic Management Options
Guidelines for Treatment
Pharmacologic Prevention and Treatment of Osteoporosis
Antiresorptive Therapy: Bisphosphonates
Antiresorptive Therapy: Hormone Therapy
Antiresorptive Therapy: Selective Estrogen Receptor Modulators
Antiresorptive Therapy: Calcitonin
Anabolic Therapy: Teriparatide
Combination Therapy
Monitoring Therapy
Summary
Self-Assessment
left_shadow

   Guidelines for Treatment

1 of 4
 

National Osteoporosis Foundation Guidelines
The practicing physician needs to determine which patients are at risk for an osteoporotic fracture and when treatment should be initiated. The NOF has developed guidelines for selecting patients who should receive treatment to reduce the risk of fracture and these are based primarily on BMD (i.e., T-scores) together with other risk factors in addition to low BMD.10 The NOF guidelines (with are based on DXA-derived T-scores determined at the hip) recommend treatment in the following clinical situations:

  • Women with T-scores below -2.0 with no risk factors
  • Women with T-scores below -1.5 with one or more risk factors for fractures
  • Women with a prior vertebral or hip fracture
The presence of a vertebral fracture significantly increases the lifetime risk of subsequent fractures and there are data to show that women who develop a vertebral fracture are at substantial risk for additional fracture within the next year.26
 
left_shadow

 

1 of 4

Copyright 1995-2006 American Medical Association. All rights reserved.